



Dear WHO EML Secretariat,

On behalf of [AEMICE – Asociación Española de Migraña y Cefalea](#), a Spanish non-profit organization, declared of public utility, which was established in 2005 with the aim of providing support and information to people with headaches in our country, representing and defending their rights and health and social needs before third parties.

We have read with extreme interest the applications

[A.10 eletriptan naproxen, migraine

A.13 fremanezumab, high frequency and chronic migraine

I.2 amitriptyline - migraine prophylaxis

I.3 bisoprolol - migraine prophylaxis

I.7 Ibuprofen - acute migraine treatment

I.10 Prednisolone, sumatriptan and verapamil - cluster headache]

I write in support of such applications because they address an important need in the general population.

Migraine and cluster headache are highly disabling chronic conditions, underdiagnosed and undertreated.

The addition of more effective drugs for their management is an important step toward better care in many countries.

Our organization is committed to supporting this initiative and is available to provide any further information or assistance. We look forward to the positive impact this development will have on the global health landscape.

Sincerely,

Ms. Isabel Colomina
President of AEMICE – Asociación Española de Migraña y Cefalea